AB ANALITICA and USTAR Biotechnology are proud to announce a strategic partnership for the distribution of EasyNAT® and MultNAT® platforms in Italy—cutting-edge solutions designed to deliver rapid, sensitive, and accessible molecular point-of-care (mPOC) diagnostics. This collaboration represents a major step forward in bringing precision medicine closer to the patient.
Founded in 1990, AB ANALITICA is a leading company in the field of molecular diagnostics. With a solid foundation in Real-Time PCR technology, the company develops high-quality in vitro diagnostic tests for infectious diseases, human genetics, and oncology—driven by a strong commitment to research, innovation, and quality.
USTAR Biotechnology, founded in 2005, is a global pioneer in molecular point-of-care diagnostics. The company is known for its groundbreaking technologies such as cross-priming amplification (CPA), disposable nucleic acid detection devices, and reagent glassification. With over 10,000 instruments deployed across more than 90 countries and certified by CE-IVDR, WHO EUL, US FDA, and others, USTAR actively partners with global health organizations such as FIND and the Stop TB Partnership.
The EasyNAT® and MultNAT® platforms offer decentralized diagnostic solutions with fast turnaround times—results can be available in under 20 minutes—minimal training requirements, and high diagnostic accuracy. They support syndromic testing for multiple pathogens, making them ideal for clinical, hospital, and community-based settings.
This strategic partnership combines AB ANALITICA’s strong local presence and diagnostic expertise with USTAR’s advanced mPOC technologies, aiming to accelerate the diagnosis of infectious diseases and antimicrobial resistance (AMR) while promoting precision medicine across Italy.
“We are excited to partner with USTAR Biotechnology,” said Dino Paladin, Founder of AB ANALITICA. “Their point-of-care innovations are a real game-changer in rapid molecular and syndromic diagnostics. Integrating EasyNAT® and MultNAT® into our portfolio enables us to offer highly innovative solutions that have a direct impact on patient care and clinical outcomes.”
With a shared vision of innovation, quality, and global health commitment, AB ANALITICA and USTAR are ready to bring the next generation of molecular diagnostics to the forefront of Italian healthcare.